Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 3/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR1B | P28222 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | HTR1E | P28566 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | HTR6 | P50406 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9726238 | 0.86 | CTSL (0.60) | CTSLHTR2AADRB1HTR1AADRA2A | |
| SCHEMBL9728200 | 0.86 | CTSL (0.62) | CTSLHTR2AADRB1HTR1AADRA2A | |
| SCHEMBL12126312 | 0.86 | CTSL (0.62) | CTSLHTR2AADRB1HTR1AADRA2A | |
| SCHEMBL15722175 | 0.86 | CTSL (0.62) | CTSLHTR2AADRB1HTR1AADRA2A | |
| SCHEMBL14532871 | 0.85 | CTSL (0.63) | CTSLHTR2AADRB1HTR1AADRA2A | |
| SCHEMBL18232022 | 0.84 | CTSL (0.71) | CTSLKDM4EMAPTPOLBAPAF1 | |
| SCHEMBL19102501 | 0.84 | CTSL (0.56) | CTSLHTR2AADRB1HTR1AADRA2A | |
| SCHEMBL180565 | 0.83 | CTSL (0.60) | CTSLHTR2AADRB1HTR1AADRA2A | |
| SCHEMBL16190432 | 0.83 | CTSL (0.60) | CTSLHTR2AADRB1HTR1AADRA2A | |
| SCHEMBL14534876 | 0.83 | CTSL (0.60) | CTSLHTR2AADRB1HTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676850-B2 | Anti SEZ6 antibodies and methods of use | ABBVIE STEMCENTRX LLC (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2352821-B1 | MEGANUCLEASE VARIANTS CLEAVING A DNA TARGET SEQUENCE FROM A GLUTAMINE SYNTHETASE GENE AND USES THEREOF | CELLECTIS (FR) | 2016-11-23 | — | — | EP | disclosed |
| US-20160213039-A1 | STEVIOL GLYCOSIDES | DSM IP ASSETS B.V. (NL) | 2016-07-28 | — | — | US | disclosed |
| US-20160185813-A1 | RECOVERY OF STEVIOL GLYCOSIDES | DSM IP ASSETS B.V. (NL) | 2016-06-30 | — | — | US | disclosed |
| US-9273296-B2 | Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof | CELLECTIS (FR) | 2016-03-01 | — | — | US | disclosed |
| US-9211303-B2 | Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes | NATIONAL YANG-MING UNIVERSITY (TW) | 2015-12-15 | — | — | US | disclosed |
| EP-2137536-B1 | METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS BY STIMULATING ER STRESS | UNIV SOUTHERN CALIFORNIA USC STEVENS (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2829599-A1 | METHOD FOR INTRODUCING EXOGENOUS DNA BY OVERCOMING RESTRICTION MODIFICATION BARRIER OF TARGET BACTERIUM | Institute Of Microbiology, Chinese Academy Of Sciences (CN) | 2015-01-28 | — | — | EP | disclosed |
| US-20140178384-A1 | POST-TRANSLATIONALLY MODIFIED NEUROTROPHINS | INSTITUT PASTEUR (FR) | 2014-06-26 | — | — | US | disclosed |
| US-20130209437-A1 | I-CREI HOMING ENDONUCLEASE VARIANTS HAVING NOVEL CLEAVAGE SPECIFICITY AND USE THEREOF | CELLECTIS (FR) | 2013-08-15 | — | — | US | disclosed |
| US-8227241-B2 | Bacterial host cell for the direct expression of peptides | UNIGENE LABORATORIES, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20120107341-A1 | METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS | Oregon Health & Science University and The Govt. of the USA, dba The Dep. of Veterans Affairs | 2012-05-03 | — | — | US | disclosed |
| US-20110213105-A1 | Control over controlled radical polymerization processes | U.S. BANK NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2011-09-01 | — | — | US | disclosed |
| US-20110183396-A1 | PRODUCTION AND USE OF YEAST HAVING INCREASED CELLULOSE HYDROLYSIS ABILITY | KANSAI CHEMICAL ENGINEERING CO., LTD. (JP) | 2011-07-28 | — | — | US | disclosed |
| US-20110169805-A1 | ELECTRIC OPTICAL APPARATUS, DRIVING METHOD THEREOF AND ELECTRONIC DEVICE | SEIKO EPSON CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20100273949-A1 | Star macromolecules for personal and home care | U.S. BANK NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2010-10-28 | — | — | US | disclosed |
| US-20070085227-A1 | Multi-phase contacting process using microchannel technology | VELOCYS INC. | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213039-A1 | STEVIOL GLYCOSIDES | TAS2R7, SUCLG1, TAS2R40 | CTSL 3778/4885HTR2A 3222/4885ADRB1 4457/4885 |
| US-20160185813-A1 | RECOVERY OF STEVIOL GLYCOSIDES | SORD, SPR, SUCLG2 | CTSL 3626/4885HTR2A 3871/4885ADRB1 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.